Free press releases distribution network?

Agency / Source: MarketResearch.com

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!



MarketResearch.com Adds New Report on Melanoma Treatments - MarketResearch.com has added a new report, “Stakeholder Opinions: Melanoma Future treatment will be based on individual tumor gene expression signatures,” which focuses on current melanoma issues and developing treatment methods
MarketResearch.com Adds New Report on Melanoma Treatments

 

PRZOOM - /newswire/ - Rockville, MD, United States, 2010/06/28 - MarketResearch.com has added a new report, “Stakeholder Opinions: Melanoma Future treatment will be based on individual tumor gene expression signatures,” which focuses on current melanoma issues and developing treatment methods.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

MarketResearch.com has announced the addition of Datamonitor’s new report “Stakeholder Opinions: Melanoma Future treatment will be based on individual tumor gene expression signatures,” to their collection of Biotechnology market reports.

The majority of patients present with early-stage melanoma, when surgery is often curative. Patients with metastatic disease are poorly served by current drugs, with very few approved treatment options and no widely accepted standard of care. A significant unmet need therefore remains for more effective agents, which has made melanoma a popular R&D target.

Most melanoma is diagnosed at an early stage, with surgery proving curative in many patients. For advanced disease, current treatment options are inadequate, with only three approved drugs: interferon alpha-2b in the adjuvant setting, and dacarbazine and interleukin-2 for metastatic disease. Most patients are therefore treated in clinical trials.

Approved products for melanoma confer only mediocre response rates with minimal effects on survival, and high levels of toxicity, thus restricting their use to certain patients. Unmet needs therefore prevail, highlighting the urgent need to develop novel therapeutics offering significant clinical improvements over existing treatment options.

Melanoma has emerged as a relatively popular R&D target for oncology drug developers, with 11 products currently in late-phase development. While incidence of melanoma is not as high as that of the 'big four' tumor types, it is still substantial, which could result in significant financial reward if a pipeline product shows positive results.

Topics covered in the report include:

• Melanoma overview, including definition, risk factors, epidemiology forecasts and discussion of unmet needs;
• Current diagnosis and treatment of melanoma, including drug regimens used by stage and ongoing controversies;
• Examination of the late-phase melanoma pipeline and market opportunities for drug developers;
• Stakeholder opinions based on qualitative interviews with key opinion leaders in the field of melanoma.

For more information, visit marketresearch.com/.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: MarketResearch.com

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick PRZOOM - Press & Newswire Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


MarketResearch.com Adds New Report on Melanoma Treatments

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name PRZOOM - Press & Newswire and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
|
Contact: Veronica Franco - MarketResearch.com 
240-747-3016 vfranco[.]marketresearch.com
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any MarketResearch.com securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!




Read Latest Press Releases From MarketResearch.com / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Press Releases:

FDA Grants Breakthrough Therapy Designation for Rituxan® (Rituximab) in Pemphigus Vulgaris
MDxHealth Signs Agreement with Lab21 to Make SelectMDx Liquid Biopsy Test Available in the United Kingdom
Greenphire Drives Global Site Adoption of Clinical Trial Payment Solutions
SelectMDx Chosen by Michigan Medicine as Pre-biopsy Diagnostic Tool in Groundbreaking US Prostate Cancer Risk Clinic
BTG Announces CE Mark Certification for DC Bead LUMI™ - The First Commercially Available Radiopaque Drug-Eluting Bead
Sartorius to Acquire Real-time Live-cell Analysis Pioneer and Leader Essen BioScience
Pyxis™ ES System to Help U.S. Department of Defense Advance Medication Safety and Patient Care
BTG Receives U.S. FDA 510(k) Clearance for EKOS® Control Unit 4.0
MDxHealth Announces Agreement with Istituto Diagnostico Varelli for Distribution of SelectMDx Throughout Central-South Italy
BD Veritor™ System Meets FDA’s New Performance Requirements for Rapid Influenza Antigen Detection Tests

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
 
NewswireToday Celebrates 10 Years in Business
Find business coaching, life coaching, executive coaching and corporate coaching, best selling coaching books, ...



PREMIUM Members


Visit  MagLar, Inc.

Visit  La Bella Bakery Artisan Bakery Arizona

Visit  JobsWare.com







 
  ©2017 PRZOOM — Limelon Advertising, Co.
Home | About PRZOOM | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneur newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today